Glucose-6-phosphate dehydrogenase deficiency

Disadvantages and possible benefits

Genesia Manganelli, Ugo Masullo, Stefania Passarelli, Stefania Filosa

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase. This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors. G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.

Original languageEnglish
Pages (from-to)73-82
Number of pages10
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume13
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Glucosephosphate Dehydrogenase Deficiency
Glucosephosphate Dehydrogenase
Pentose Phosphate Pathway
Enzymes
Erythrocytes
NADPH Dehydrogenase
X Chromosome Inactivation
X-Linked Genes
Essential Genes
NADP
Malaria
Coronary Disease
Neoplasms
Pharmaceutical Preparations

Keywords

  • Cancer
  • Cardiovascular diseases
  • Development
  • G6PD deficiency
  • Longevity
  • Malaria
  • Oxidative stress
  • Stem cell differentiation

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Glucose-6-phosphate dehydrogenase deficiency : Disadvantages and possible benefits. / Manganelli, Genesia; Masullo, Ugo; Passarelli, Stefania; Filosa, Stefania.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 13, No. 1, 2013, p. 73-82.

Research output: Contribution to journalArticle

@article{bf151165f6ce44ecb6ab017d2edd3d9a,
title = "Glucose-6-phosphate dehydrogenase deficiency: Disadvantages and possible benefits",
abstract = "We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase. This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors. G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.",
keywords = "Cancer, Cardiovascular diseases, Development, G6PD deficiency, Longevity, Malaria, Oxidative stress, Stem cell differentiation",
author = "Genesia Manganelli and Ugo Masullo and Stefania Passarelli and Stefania Filosa",
year = "2013",
doi = "10.2174/1871529X11313010008",
language = "English",
volume = "13",
pages = "73--82",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Glucose-6-phosphate dehydrogenase deficiency

T2 - Disadvantages and possible benefits

AU - Manganelli, Genesia

AU - Masullo, Ugo

AU - Passarelli, Stefania

AU - Filosa, Stefania

PY - 2013

Y1 - 2013

N2 - We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase. This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors. G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.

AB - We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase. This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors. G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.

KW - Cancer

KW - Cardiovascular diseases

KW - Development

KW - G6PD deficiency

KW - Longevity

KW - Malaria

KW - Oxidative stress

KW - Stem cell differentiation

UR - http://www.scopus.com/inward/record.url?scp=84876712745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876712745&partnerID=8YFLogxK

U2 - 10.2174/1871529X11313010008

DO - 10.2174/1871529X11313010008

M3 - Article

VL - 13

SP - 73

EP - 82

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 1

ER -